Clinical trial
A Multicenter, Single-group, Phase III Study to Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years Who Completed the Primary Vaccination Against Diphtheria, Tetanus, Pertussis, and Poliomyelitis by Participating in the Phase III Study, BR-DTPP-CT-301, or by Receiving Routine Vaccination
NCT04618640 is registered in ClinicalTrials.gov with Boryung Biopharma Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Single-group, Phase III Study to Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years Who Completed the Primary Vaccination Against Diphtheria, Tetanus, Pertussis, and Poliomyelitis by Participating in the Phase III Study, BR-DTPP-CT-301, or by Receiving Routine Vaccination
- Lead sponsor
- Boryung Biopharma Co., Ltd.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- December 26, 2019
- Completion date
- July 30, 2021
- Enrollment
- 249 (estimated)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.
diphtheria, pertussis, poliomyelitis, tetanus